Company Profile

Shilpa Medicare’s marketing partner -- Amneal Pharmaceuticals has launched PEMRYDI RTU (Pemetrexed injection 10 mg/mL), the first ready-to-use pemetrexed formulation in the US market. The product has already been granted permanent J-code (J9324) by U.S. Centers for Medicare & Medicaid Services (CMS). 

Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents. It is also indicated in the treatment of mesothelioma in combination with cisplatin. PEMRYDI RTU is a novel ready-to-use injection which eliminates the need for refrigeration or reconstitution and dilution for administration to the patient. 

This offers hospitals and oncology clinics a new, value-added presentation that should improve pharmacy efficiency by eliminating preparation steps and freeing up refrigerator space. Currently product is available in two vial sizes: 100mg/10mL and 500 mg/50mL, and it intends to introduce 1000mg/100mL soon in the market. According to IQVIA, U.S. annual sales for pemetrexed for the 12 months ended February 2024 were $287 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare has informed that the company's marketing partner, Amneal Pharmaceuticals, has launched PEMRYDI RTU® (Pemetrexed injection 10 mg/mL), the first ready-to-use pemetrexed formulation in the US market. The product has already been granted permanent J-code (J9324) by U.S. Centers for Medicare & Medicaid Services (CMS).

The above information is a part of company’s filings submitted to BSE.

Austrian Agency for Health and Food Safety (AGES) has issued GMP certification to Shilpa Medicare’s Unit 4, Jadcherla, Telangana. The said unit was inspected from January 22, 2024 to January 26, 2024. The previous EU - GMP inspection for this facility was in January 2020.

This unit of Shilpa Medicare is engaged in the manufacture, testing and distribution of sterile Injections and non-sterile tablets and Capsule finished dosage forms in the US, Europe and rest of the world markets. This inspection will facilitate continued supply of medicines for commercial distribution to various countries of the European Union from this unit.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare has raised Rs 499.99 crore through qualified institutional placement (QIP) of equity shares. The issue opened on April 08, 2024 and closed on April 12, 2024. 
Pursuant to the allotment of Equity Shares in the Issue, the paid-up equity share capital of the Company stands increased from Rs 8,68,01,898 comprising of 8,68,01,898 Equity Shares of face value of Rs 1 each to Rs 9,77,90,908, comprising of 9,77,90,908 Equity Shares of face value of Rs 1 each.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare is currently trading at Rs. 513.25, up by 8.65 points or 1.71% from its previous closing of Rs. 504.60 on the BSE.

The scrip opened at Rs. 501.05 and has touched a high and low of Rs. 518.55 and Rs. 486.95 respectively. So far 35076 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 533.90 on 09-Apr-2024 and a 52 week low of Rs. 228.25 on 06-Jun-2023.

Last one week high and low of the scrip stood at Rs. 533.90 and Rs. 486.95 respectively. The current market cap of the company is Rs. 4450.33 crore.

The promoters holding in the company stood at 50.01%, while Institutions and Non-Institutions held 8.58% and 41.41% respectively.

Shilpa Medicare has raised Rs 499.99 crore through qualified institutional placement (QIP) of equity shares. The issue opened on April 08, 2024 and closed on April 12, 2024. 

Pursuant to the allotment of Equity Shares in the Issue, the paid-up equity share capital of the Company stands increased from Rs 8,68,01,898 comprising of 8,68,01,898 Equity Shares of face value of Rs 1 each to Rs 9,77,90,908, comprising of 9,77,90,908 Equity Shares of face value of Rs 1 each.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.